Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
EBS Emergent BioSolutions Inc
- Stocks
- Healthcare
- NYSE: EBS
Price (delayed)
$5.41
Market cap
$293.64M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.54
Enterprise value
$806.54M
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated
Highlights
EBS's quick ratio has soared by 99% QoQ
The net income has soared by 77% YoY and by 31% from the previous quarter
EBS's equity is down by 17% year-on-year but it is up by 14% since the previous quarter
EBS's gross profit is down by 30% year-on-year and by 6% since the previous quarter
The company's revenue fell by 19% YoY and by 7% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.emergentbiosolutions.com
Key stats
What are the main financial stats of EBS
Market
Valuations
Earnings
Shares outstanding
54.28M
Market cap
$293.64M
Enterprise value
$806.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
0.3
EV/EBIT
N/A
EV/EBITDA
7.65
EV/Sales
0.84
Revenue
$965.4M
Gross profit
$340.2M
Operating income
-$98.6M
Net income
-$131.6M
EBIT
-$900,000
EBITDA
$105.4M
Free cash flow
$140.4M
Per share
Balance sheet
Liquidity
EPS
-$2.54
EPS diluted
-$2.7
Free cash flow per share
$2.58
Book value per share
$10.17
Revenue per share
$17.75
TBVPS
$17.3
Total assets
$1.43B
Total liabilities
$873.4M
Debt
$665.7M
Equity
$552.7M
Working capital
$594.9M
Debt to equity
1.2
Current ratio
6.32
Quick ratio
3.19
Net debt/EBITDA
4.87
Margins
Efficiency
Dividend
EBITDA margin
10.9%
Gross margin
35.2%
Net margin
-13.6%
Operating margin
-10.2%
Return on assets
-9.1%
Return on equity
-27.3%
Return on invested capital
-0.1%
Return on capital employed
-0.1%
Return on sales
-0.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EBS stock price
How has the Emergent BioSolutions stock price performed over time
Intraday
-4.08%
1 week
-14.94%
1 month
16.85%
1 year
-5.25%
YTD
-43.41%
QTD
11.32%
Financial performance
How have Emergent BioSolutions's revenue and profit performed over time
Revenue
$965.4M
Gross profit
$340.2M
Operating income
-$98.6M
Net income
-$131.6M
Gross margin
35.2%
Net margin
-13.6%
EBS's operating income has soared by 82% YoY and by 9% from the previous quarter
The company's operating margin has surged by 78% YoY
The net income has soared by 77% YoY and by 31% from the previous quarter
Emergent BioSolutions's net margin has surged by 71% YoY and by 26% QoQ
Price vs fundamentals
How does EBS's price correlate with its fundamentals
Growth
What is Emergent BioSolutions's growth rate over time
Valuation
What is Emergent BioSolutions stock price valuation
P/E
N/A
P/B
0.53
P/S
0.3
EV/EBIT
N/A
EV/EBITDA
7.65
EV/Sales
0.84
EBS's EPS has soared by 77% year-on-year and by 29% since the previous quarter
The price to book (P/B) is 61% lower than the 5-year quarterly average of 1.4 and 31% lower than the last 4 quarters average of 0.8
EBS's equity is down by 17% year-on-year but it is up by 14% since the previous quarter
The P/S is 73% below the 5-year quarterly average of 1.2 and 20% below the last 4 quarters average of 0.4
The company's revenue fell by 19% YoY and by 7% QoQ
Efficiency
How efficient is Emergent BioSolutions business performance
EBS's ROIC has soared by 100% YoY and by 98% QoQ
EBS's ROS has soared by 100% year-on-year and by 99% since the previous quarter
The company's return on assets has surged by 69% YoY and by 26% QoQ
EBS's return on equity has surged by 64% year-on-year and by 27% since the previous quarter
Dividends
What is EBS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EBS.
Financial health
How did Emergent BioSolutions financials performed over time
The total assets is 63% more than the total liabilities
EBS's quick ratio has soared by 99% QoQ
Emergent BioSolutions's current ratio has soared by 71% from the previous quarter
Emergent BioSolutions's debt is 20% higher than its equity
Emergent BioSolutions's debt has decreased by 27% YoY
EBS's equity is down by 17% year-on-year but it is up by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.